• Revenue down 2.9% to US$6.12 million
• Net loss up 74.0% to US$4.88 million
• Adjusted EBITDA loss of US$1.38 million

Lumos Diagnostics Holdings Limited reported a net loss after tax of US$4.88 million for the half-year ended 31 December 2025, up 74.0% from the prior corresponding period. The increase in net loss was largely driven by financing costs associated with the loan facility and employee share-based payments expense, both of which are non-cash items. During the period, Lumos recorded revenues of US$6.12 million, down 2.9% from the prior half-year, with US$4.44 million generated from contract development and manufacturing services and US$1.68 million from the sale of Lumos' point-of-care diagnostic test products. The adjusted EBITDA loss for the period was US$1.38 million, an increase of US$0.44 million, primarily driven by investments in sales and marketing, and internal product development costs. Lumos continued to work on delivering against its project pipeline, both in the infectious disease market and other commercial applications, including in women's health. The company also secured a follow-on development contract with Aptatek Biosciences to advance the PheCheck aptamer-based, in-home monitoring tool for the screening and management of phenylketonuria (PKU).